- OXB has launched a fast-track development and manufacturing offering to accelerate GMP production timelines for AAV and lentiviral vectors.
- The program reduces AAV timelines from ~15 months to as little as seven months and lentiviral timelines from 12–18 months to as little as nine months.
OXB has announced the launch of a fast-track development and manufacturing offering aimed at accelerating GMP production timelines for clients working with lentiviral (LV) and adeno-associated viral (AAV) vectors. The CDMO stated that the new service is designed to provide an expedited route to clinical readiness for eligible biotech programs.
The offering uses OXB’s proprietary inAAVate™ and LentiVector™ platforms and has been introduced in response to increased client demand for faster and more cost-effective development pathways. According to the company, the initiative is intended to help biopharma clients reach clinical and regulatory milestones earlier, supporting faster access to therapies for patients.
For AAV vectors, the fast-track program reduces the pathway to GMP manufacturing from an industry standard of approximately 15 months to as little as seven months. The company attributes this reduction to its plug-and-play platform, which minimizes development steps while maintaining performance and consistency, along with in-house analytical development capabilities.
For lentiviral vectors, the contract manufacturing timeline is reduced from an industry standard of 12–18 months to as little as nine months. This is achieved through the use of platform datasets, advanced analytics, and a streamlined transition from scale-down models directly into GMP manufacturing. Additional efficiencies are gained by integrating vector design, production, purification, and fill-finish processes.
“For emerging cell and gene therapy companies, viral vector development and manufacture represents a frequent bottleneck to clinical readiness, and issues can delay critical clinical milestones. The launch of our fast-track offering will make our proprietary inAAVate™ and LentiVector™ platforms accessible to a wider range of clients who are looking for an expedited route to GMP manufacture and the clinic, cutting industry standard development timelines by up to 50%.”
Dr. Sébastien Ribault, Chief Business Officer of OXB
